MEDEXUS
PharmaMEDEXUS is a pharmaceutical company focused on Oncology. Key products include GRAFAPEX.
FDA Novel Drug Designations
(2025)See 1 novel approval →
MEDEXUS's Key Drugs
MEDEXUS's core commercial portfolio centers on GRAFAPEX, spanning Oncology — its most strategically important drugs approved in the last 15 years.
MEDEXUS's Recent FDA Approvals
MEDEXUS secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
MEDEXUS's Therapeutic Areas
MEDEXUS's approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
MEDEXUS's Top Competitors
MEDEXUS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
MEDEXUS Pipeline Snapshot
Active clinical trials for MEDEXUS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • GRAFAPEX leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling